[Therapeutic drug monitoring of olanzapine].
Suivi thérapeutique pharmacologique de l’olanzapine.
Level of evidence
Niveau de preuve
Olanzapine
Suivi thérapeutique pharmacologique
Therapeutic drug monitoring
Journal
Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544
Informations de publication
Date de publication:
Historique:
received:
02
06
2015
accepted:
19
06
2015
medline:
30
10
2016
pubmed:
30
10
2016
entrez:
30
10
2016
Statut:
ppublish
Résumé
Olanzapine, atypical antipsychotic, is used to treat schizophrenia and bipolar disorder. Its therapeutic drug monitoring (TDM) is quite commonly done. Olanzapine is well absorbed orally (bioavailability: 85 %), with peak plasma occurring between 4 and 6hours after oral administration. It is extensively metabolized by different hepatic enzymes (including CYP1A2 and CYP2D6 isoforms) to a large number of inactive metabolites, and its half-life is between 30 and 60hours. No specific therapeutic range, or threshold concentration could not be a consensus, but the higher intra- and interindividual variability, as well as the existence of studies suggesting a correlation between circulating concentrations of olanzapine and occurrence of therapeutic relapse or toxic phenomena appear to justify the STP for this molecule. Given these data, the interest of the STP was evaluated for this molecule to: recommended with therapeutic window of 20μg/L to 80μg/L.
Identifiants
pubmed: 27793422
pii: S0040-5957(16)30042-7
doi: 10.2515/therapie/2015040
pii:
doi:
Types de publication
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
S75-S80Informations de copyright
Copyright © 2016 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.